
Ursula A. Matulonis, MD, discusses the impact of PARP inhibitors on ovarian cancer treatment.

Your AI-Trained Oncology Knowledge Connection!


Ursula A. Matulonis, MD, discusses the impact of PARP inhibitors on ovarian cancer treatment.

Ursula Matulonis, MD, medical director of Gynecologic Oncology at Dana-Farber Cancer Institute, discusses two upcoming trials for both platinum-resistant and platinum-sensitive recurrent ovarian cancer.

Published: March 10th 2022 | Updated:

Published: March 24th 2016 | Updated: